iOmx refuels with $75M+ on its search for immune checkpoint targets on tumor cells
While a big chunk of oncology research is focused on targeting T-cell regulators to stamp out cancer, iOmx Therapeutics is homing in on immune checkpoint targets on tumor cells — and it’s just received another $75.3 million to fuel their push toward the clinic.
iOmx unveiled the €65 million Series B round on Tuesday morning, roughly five years after emerging from stealth. The new cash will help the startup put its first candidate, an SIK3 kinase inhibitor called IMT-07, in the clinic late next year for solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.